Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can thalidomide improve outcome in patients with multiple myeloma?

Nature Clinical Practice Oncology volume 3, pages 590–591 (2006)Cite this article

boxed-textBarlogie B et al. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354: 1021–1030

Thalidomide improves response and event-free survival rates in myeloma patients receiving autologous stem-cell transplantation, with comparable overall survival after relapse from tandem transplant versus when used from the outset

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Munshi NC and Anderson KC (2005) To transplant or not to transplant? Blood 106: 3687–3688

    Article  CAS  Google Scholar 

  2. Singhal S et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565–1571

    Article  CAS  Google Scholar 

  3. Richardson P et al. (2004) Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 79: 875–882

    Article  CAS  Google Scholar 

  4. Richardson PG et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063–3067

    Article  CAS  Google Scholar 

  5. Rajkumar SV et al. (2006) Phase III clinical trial of thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24: 431–436

    Article  CAS  Google Scholar 

  6. Attal M et al. ((2006) Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood Jul 27 [Epub ahead of print]

  7. Barlogie B et al. (2006) Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107: 2633–2638

    Article  CAS  Google Scholar 

  8. Palumbo A et al. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367: 825–831

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. the Clinical Director of the Jerome Lipper Multiple Myeloma Center (JLMMC) at the Dana-Farber Cancer Institute (DFCI), Boston, MA, USA

    Paul G Richardson

  2. Instructor in Medicine at Harvard Medical School (HMS), the Department of Medical Oncology of DFCI and the Department of Medicine at Brigham and Women's Hospital, Boston, MA, USA

    Constantine S Mitsiades

  3. the Associate Director of the JLMMC of DFCI, Boston, MA, USA

    Nikhil C Munshi

  4. Associate Professor of Medicine at HMS, Boston, MA, USA

    Nikhil C Munshi

  5. the Director of the JLMMC, Boston, MA, USA

    Kenneth C Anderson

  6. Chief of Division of Hematologic Neoplasia at DFCI and the Kraft Family Professor of Medicine at HMS, Boston, MA, USA

    Kenneth C Anderson

Authors
  1. Paul G Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Constantine S Mitsiades
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nikhil C Munshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenneth C Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth C Anderson.

Ethics declarations

Competing interests

PG Richardson is on the Advisory Board and Speakers' Bureau for Celgene Corporation, and for Millennium Pharmaceuticals. CS Mitsiades is a consultant and receives honoraria from Millennium Pharmaceuticals, Novartis Pharmaceuticals, Bristol-Myers Squibb and Merck & Co. NC Munshi is on the Advisory Board and Speakers' Bureau for Celgene Corporation, Millennium Pharmaceuticals and Novartis Pharmaceuticals. KC Anderson is a consultant and receives honoraria and research support from Celgene Corporation, Millennium Pharmaceuticals and Novartis Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richardson, P., Mitsiades, C., Munshi, N. et al. Can thalidomide improve outcome in patients with multiple myeloma?. Nat Rev Clin Oncol 3, 590–591 (2006). https://doi.org/10.1038/ncponc0630

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0630

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing